This brand name is authorized in Nigeria
The drug REESHAPE contains one active pharmaceutical ingredient (API):
|
1
Orlistat
UNII 95M8R751W8 - ORLISTAT
|
|
Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A08AB01 | Orlistat | A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AB Peripherally acting antiobesity products |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NG | Registered Drug Product Database | Identifier(s): A4-7211 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
